Connect the Dots

Organization

Pharmaceutical Research and Manufacturers of America

Trade group of the large U.S. drug and biotech companies; known as PhRMA.

6 links, 5 backed by primary records

Play the story Explore connections

Also known as
PhRMA
Wikidata
Q5683113
Over time
  1. CEO Billy Tauzin 2005 –

Connections 6

CEO

authored

Timeline 6 dates
  1. 2005 – Billy Tauzin CEO of Pharmaceutical Research and Manufacturers of America
  2. 2009 Pharmaceutical Research and Manufacturers of America authored PhRMA lobbying reports, 2009
  3. 2015 Pharmaceutical Research and Manufacturers of America authored PhRMA lobbying reports, 2015
  4. 2019 Pharmaceutical Research and Manufacturers of America authored PhRMA lobbying reports, 2019
  5. 2022 Pharmaceutical Research and Manufacturers of America authored PhRMA lobbying reports, 2022
  6. 2023 Pharmaceutical Research and Manufacturers of America authored PhRMA lobbying reports, 2023
Proof 22 sources
  1. Tauzin Named President of PhRMA, Roll Call, 15 Dec 2004. Scholarship & press
    has been hired as president and CEO of the Pharmaceutical Research and Manufacturers of America
    a Tauzin aide acknowledged the lawmaker had been first approached by the drug association in mid-January
  2. Tauzin aided drug firms, then they hired him, NBC News, 22 Mar 2006. Scholarship & press
    He started the day after his last term in Congress ended
    a number of reports at the time pegged his annual compensation from PhRMA at between $1 million and $2 million
    insisting that there was no relationship between his work on the Medicare bill and the new job
    to deny allegations that he was negotiating the PhRMA job while working on the Medicare law
    But even if Tauzin had done what he denies, he would have broken no laws, watchdog groups agree.
    In December 2003, the same month that President Bush signed the bill, the Pharmaceutical Research and Manufacturers of America
    House Minority Leader Nancy Pelosi called Tauzin’s consideration of the PhRMA job “inappropriate"
  3. PhRMA lobbying report (LD-2), first quarter 2009, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2009. Primary record
    6,910,000.00
  4. PhRMA lobbying report (LD-2), second quarter 2009, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2009. Primary record
    6,150,000.00
  5. PhRMA lobbying report (LD-2), third quarter 2009, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2009. Primary record
    6,790,000.00
  6. PhRMA lobbying report (LD-2), fourth quarter 2009, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2009. Primary record
    6,300,520.00
  7. PhRMA lobbying report (LD-2), first quarter 2015, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2015. Primary record
    5,440,000.00
  8. PhRMA lobbying report (LD-2), second quarter 2015, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2015. Primary record
    4,820,000.00
  9. PhRMA lobbying report (LD-2), third quarter 2015, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2015. Primary record
    4,240,000.00
  10. PhRMA lobbying report (LD-2), fourth quarter 2015, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2015. Primary record
    3,820,000.00
  11. PhRMA lobbying report (LD-2), first quarter 2019, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2019. Primary record
    9,910,000.00
  12. PhRMA lobbying report (LD-2), second quarter 2019, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2019. Primary record
    6,310,000.00
  13. PhRMA lobbying report (LD-2), third quarter 2019, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2019. Primary record
    6,230,000.00
  14. PhRMA lobbying report (LD-2), fourth quarter 2019, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2019. Primary record
    6,450,000.00
  15. PhRMA lobbying report (LD-2), first quarter 2022, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2022. Primary record
    8,070,000.00
    PDUFA reauthorization
  16. PhRMA lobbying report (LD-2), second quarter 2022, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2022. Primary record
    6,340,000.00
  17. PhRMA lobbying report (LD-2), third quarter 2022, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2022. Primary record
    7,270,000.00
  18. PhRMA lobbying report (LD-2), fourth quarter 2022, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2022. Primary record
    6,610,000.00
  19. PhRMA lobbying report (LD-2), first quarter 2023, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2023. Primary record
    7,990,000.00
  20. PhRMA lobbying report (LD-2), second quarter 2023, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2023. Primary record
    6,300,000.00
  21. PhRMA lobbying report (LD-2), third quarter 2023, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2023. Primary record
    6,370,000.00
  22. PhRMA lobbying report (LD-2), fourth quarter 2023, Secretary of the Senate and Clerk of the House (lobbying disclosure), 2023. Primary record
    6,430,000.00
Page history 1 change
  1. Add 55 stories, each checked against its sourcesAlibek96e92fe6

Something wrong or missing? Tell us, with a source, or edit this page.